Collegium Pharmaceutical/$COLL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
- Ticker
- $COLL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 423
- Headquarters
- Stoughton, United States
- Website
- www.collegiumpharma.com
COLL Metrics
BasicAdvanced
$768M
21.83
$1.13
0.73
-
Price and volume
Market cap
$768M
Beta
0.73
52-week high
$50.79
52-week low
$21.43
Average daily volume
631K
Financial strength
Current ratio
1.014
Quick ratio
0.755
Long term debt to equity
3.864
Total debt to equity
4.074
Interest coverage (TTM)
2.44%
Profitability
EBITDA (TTM)
419.618
Gross margin (TTM)
89.40%
Net profit margin (TTM)
4.68%
Operating margin (TTM)
22.90%
Effective tax rate (TTM)
9.45%
Revenue per employee (TTM)
$1,930,000
Management effectiveness
Return on assets (TTM)
6.30%
Return on equity (TTM)
13.36%
Valuation
Price to earnings (TTM)
21.826
Price to revenue (TTM)
0.97
Price to book
2.59
Price to tangible book (TTM)
-0.74
Price to free cash flow (TTM)
2.351
Free cash flow yield (TTM)
42.54%
Free cash flow per share (TTM)
10.515
Growth
Revenue change (TTM)
7.68%
Earnings per share change (TTM)
-30.32%
3-year revenue growth (CAGR)
14.25%
10-year revenue growth (CAGR)
113.83%
3-year earnings per share growth (CAGR)
64.96%
10-year earnings per share growth (CAGR)
-10.31%
What the Analysts think about COLL
Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
Analyst projections of the future price of Collegium Pharmaceutical stock.
Bulls say / Bears say
JORNAY PM is gaining traction: Q3 revenue rose 24% year on year, prescriptions grew 16%, and the number of prescribers reached a record. That gives Collegium a clear growth engine beyond its legacy pain products. (Collegium Pharmaceutical)
AZSTARYS adds a second ADHD product: it generated $26.5 million in its first full quarter under Collegium, with prescriptions up nearly 2% year on year after declining in 2025. Its patent protection is expected to extend through 2037, giving the company time to build the brand. (Collegium Pharmaceutical, Collegium Pharmaceutical)
Xtampza ER could get a lift from exclusive formulary placement with a large payer covering about 15 million people, starting in January 2027. Prescriptions also rose about 3% sequentially in Q3, despite lower reported revenue. (The Motley Fool)
The pain portfolio is eroding: Q3 revenue fell 18% year on year, with Nucynta down 44% amid generic competition and Xtampza down 9%. This decline is already offsetting growth in ADHD. (Collegium Pharmaceutical)
Belbuca faces a potential generic entrant after a settlement date of 23 January 2027. Teva would still need FDA approval, but a launch could put pressure on a product that generated $57.7 million in Q3 revenue. (The Motley Fool)
Profitability weakened in Q3: adjusted EBITDA fell 9% year on year, GAAP net income declined, and operating expenses rose 44%. Net debt stood at about 2.1 times adjusted EBITDA, leaving less room if product declines persist. (Collegium Pharmaceutical, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
COLL Financial Performance
Revenues and expenses
COLL Earnings Performance
Company profitability
Upcoming events
No upcoming events
COLL News
AllArticlesVideos
Funds containing COLL
Fund name | Fund size | $COLL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.05% |
iShares S&P SmallCap 600$IDP6 | $2.5B | 0.05% |
iShares S&P Small Cap 600£ISP6 | $2.5B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
